In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
In the same vein, Lilly's Mounjaro is approved by the FDA for diabetes, while its sibling treatment, Zepbound, is geared ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback